TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly. Cramer says Celgene, which has pulled back recently, could earn $16 a share as soon as 2017. Seattle Genetics could have the largest drug pipeline of any drugmaker that's not part of the big four.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.